Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3514 · 2 trials · 1 indication
Number of participants with adverse events
| Arm | Type | Description |
|---|---|---|
| AZD3514 | EXPERIMENTAL | Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD) |
| A | EXPERIMENTAL | Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD) |
| Name | Type | Description |
|---|---|---|
| AZD3514 | DRUG | Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout. |
Inclusion Criteria: * Males aged 20 years or older. * Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate * Documented evidence of metastatic prostate cancer * Serum testosterone concentration ≤50 ng/dL * World Health...
Top 20 of 53 competitors
AZD3514 is an investigational small molecule being studied for the treatment of prostate cancer. It is in Phase 1 clinical development and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, one in the United States, Netherlands, and United Kingdom, and another in Japanese patients.
AZD3514 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is an investigational small molecule in Phase 1 clinical development for prostate cancer.
AZD3514 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Two Phase 1 trials have been completed, but the drug remains in early-stage clinical testing for prostate cancer.
AZD3514 has been studied in two completed Phase 1 clinical trials. The first, NCT01162395, was an open-label study in prostate cancer patients in the United States, Netherlands, and United Kingdom, enrolling 64 participants. The second, NCT01351688, was an open-label study in Japanese patients with prostate cancer, enrolling 13 participants.
AZD3514 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for prostate cancer. The two clinical trials conducted so far have been completed, but the drug has not received marketing approval from the FDA or any other regulatory authority.